Efficacy of pre-emptive kidney transplantation for adults with end-stage kidney disease: a systematic review and meta-analysis.


Journal

Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128

Informations de publication

Date de publication:
Dec 2023
Historique:
entrez: 27 1 2023
pubmed: 28 1 2023
medline: 31 1 2023
Statut: ppublish

Résumé

Pre-emptive kidney transplantation (PEKT), i.e., transplantation performed before initiation of maintenance dialysis, is considered an ideal renal replacement therapy because there is no exposure to long-term dialysis therapy. Therefore, we summarized advantages/disadvantages of PEKT to assist in deciding whether kidney transplantation should be performed pre-emptively. This study was registered with PROSPERO, CRD42021269163. Observational studies comparing clinical outcomes between PEKT and non-PEKT were included; those involving only pediatric recipients or simultaneous multi-organ transplantations were excluded. The PubMed/MEDLINE, Cochrane Library, and Ichushi-Web databases were searched on 1 August 2021. Studies were pooled using the generic inverse-variance method with random effects model, and risk of bias was assessed using ROBINS-I. Seventy-six studies were included in the systematic review (sample size, 23-121,853; enrollment year, 1968-2019). PEKT patients had lower all-cause mortality (adjusted HR: 0.78 [95% CI 0.66-0.92]), and lower death-censored graft failure (0.81 [0.67-0.98]). Unadjusted RRs for the following outcomes were comparable between the two patient groups: cardiovascular disease, 0.90 (0.58-1.40); biopsy-proven acute rejection, 0.75 (0.55-1.03); cytomegalovirus infection, 1.04 (0.85-1.29); and urinary tract infection, 0.89 (0.61-1.29). Mean differences in post-transplant QOL score were comparable in both groups. The certainty of evidence for mortality and graft failure was moderate and that for other outcomes was very low following the GRADE classification. The present meta-analysis shows the potential benefits of PEKT, especially regarding patient and graft survival, and therefore PEKT is recommended for adults with end-stage kidney disease.

Sections du résumé

BACKGROUND UNASSIGNED
Pre-emptive kidney transplantation (PEKT), i.e., transplantation performed before initiation of maintenance dialysis, is considered an ideal renal replacement therapy because there is no exposure to long-term dialysis therapy. Therefore, we summarized advantages/disadvantages of PEKT to assist in deciding whether kidney transplantation should be performed pre-emptively.
METHODS UNASSIGNED
This study was registered with PROSPERO, CRD42021269163. Observational studies comparing clinical outcomes between PEKT and non-PEKT were included; those involving only pediatric recipients or simultaneous multi-organ transplantations were excluded. The PubMed/MEDLINE, Cochrane Library, and Ichushi-Web databases were searched on 1 August 2021. Studies were pooled using the generic inverse-variance method with random effects model, and risk of bias was assessed using ROBINS-I.
RESULTS UNASSIGNED
Seventy-six studies were included in the systematic review (sample size, 23-121,853; enrollment year, 1968-2019). PEKT patients had lower all-cause mortality (adjusted HR: 0.78 [95% CI 0.66-0.92]), and lower death-censored graft failure (0.81 [0.67-0.98]). Unadjusted RRs for the following outcomes were comparable between the two patient groups: cardiovascular disease, 0.90 (0.58-1.40); biopsy-proven acute rejection, 0.75 (0.55-1.03); cytomegalovirus infection, 1.04 (0.85-1.29); and urinary tract infection, 0.89 (0.61-1.29). Mean differences in post-transplant QOL score were comparable in both groups. The certainty of evidence for mortality and graft failure was moderate and that for other outcomes was very low following the GRADE classification.
CONCLUSIONS UNASSIGNED
The present meta-analysis shows the potential benefits of PEKT, especially regarding patient and graft survival, and therefore PEKT is recommended for adults with end-stage kidney disease.

Identifiants

pubmed: 36705051
doi: 10.1080/0886022X.2023.2169618
pmc: PMC9888453
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2169618

Références

Am J Transplant. 2011 Oct;11(10):2093-109
pubmed: 21883901
J Clin Epidemiol. 2019 Jul;111:105-114
pubmed: 29432858
Nephrol Dial Transplant. 2002 Sep;17(9):1684-8
pubmed: 12198224
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
JAMA Netw Open. 2020 Sep 1;3(9):e2016197
pubmed: 32902652
Nephrol Dial Transplant. 2016 May;31(5):691-7
pubmed: 26567249
Am J Transplant. 2010 Sep;10(9):2008-16
pubmed: 20645941
Clin Kidney J. 2019 Feb 26;12(5):702-720
pubmed: 31583095
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Kidney Int. 1999 Mar;55(3):1081-90
pubmed: 10027947
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1280-1282
pubmed: 29769181
Am J Kidney Dis. 2019 Mar;73(3 Suppl 1):A7-A8
pubmed: 30798791
Kidney Int. 2000 Sep;58(3):1311-7
pubmed: 10972695
PLoS Med. 2012;9(9):e1001307
pubmed: 22984353
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Nephrol Dial Transplant. 2019 Mar 1;34(3):538-545
pubmed: 29579221
Am J Kidney Dis. 1998 Jul;32(1):93-100
pubmed: 9669429
Transplant Proc. 2015 Apr;47(3):626-9
pubmed: 25891699
Am J Kidney Dis. 2000 Apr;35(4):611-6
pubmed: 10739780
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
N Engl J Med. 1999 Dec 2;341(23):1725-30
pubmed: 10580071
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):122-130
pubmed: 27895135
Hypertension. 1997 Dec;30(6):1425-30
pubmed: 9403563
Nephrol Dial Transplant. 2005 Jan;20(1):167-75
pubmed: 15546892
Clin J Am Soc Nephrol. 2011 Feb;6(2):303-10
pubmed: 20930091
Kidney Int. 1999 Feb;55(2):648-58
pubmed: 9987089
Am J Transplant. 2019 Dec;19(12):3367-3376
pubmed: 31132214
Transplant Proc. 2020 Apr;52(3):740-747
pubmed: 32143872
J Am Soc Nephrol. 2019 Sep;30(9):1697-1707
pubmed: 31308074
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1484-1492
pubmed: 31455690
Transplantation. 2007 Jan 27;83(2):144-9
pubmed: 17264810
PLoS One. 2012;7(1):e29591
pubmed: 22279541
J Am Soc Nephrol. 2005 Feb;16(2):496-506
pubmed: 15615820

Auteurs

Tatsuhiko Azegami (T)

Keio University Health Center, Yokohama, Japan.
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Noriyuki Kounoue (N)

Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.

Tadashi Sofue (T)

Department of Cardiovascular and Cerebrovascular Medicine, Kagawa University, Takamatsu, Japan.

Masahiko Yazawa (M)

Department of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Japan.

Makoto Tsujita (M)

Department of Nephrology, Masuko Memorial Hospital, Nagoya, Japan.

Kosuke Masutani (K)

Department of Internal Medicine, Faculty of Medicine, Division of Nephrology and Rheumatology, Fukuoka University, Fukuoka, Japan.

Yuki Kataoka (Y)

Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.
Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.
Department of Community Medicine, Section of Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.

Hideyo Oguchi (H)

Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH